Gilead Sciences Inc Stock
Gilead Sciences Inc Stock
We can see a decrease in the price for Gilead Sciences Inc. Compared to yesterday it has lost -€1.240 (-1.050%).
With 55 Buy predictions and not a single Sell prediction Gilead Sciences Inc is an absolute favorite of our community.
As a result the target price of 124 € shows a slightly positive potential of 6.02% compared to the current price of 116.96 € for Gilead Sciences Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Gilead Sciences Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Gilead Sciences Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gilead Sciences Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | -1.050% | -2.443% | -6.885% | 29.322% | 11.488% | 56.764% | 117.800% |
| IQVIA Holdings Inc. | 0.790% | -2.630% | 1.386% | 14.035% | -24.262% | -20.343% | -15.755% |
| Incyte Corp. | -2.030% | -0.172% | 0.321% | 62.131% | -3.515% | 19.150% | 20.528% |
| Vertex Pharmaceuticals Inc. | -0.440% | -1.643% | -9.243% | -12.348% | -4.493% | 23.956% | 107.097% |
Comments
Gilead Sciences (GILD) had its price target raised by Citigroup Inc. from $156.00 to $165.00. They now have a "buy" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target raised by Morgan Stanley from $171.00 to $175.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target lowered by Cantor Fitzgerald from $155.00 to $115.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat